{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:35:12Z","timestamp":1789450512103,"version":"build-2803163510"},"reference-count":56,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100020295","name":"Natera","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020295","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Kidney Disease and Health"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1053\/j.akdh.2023.01.004","type":"journal-article","created":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T20:54:04Z","timestamp":1682110444000},"page":"261-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Drug Development in Autosomal Dominant Polycystic Kidney Disease: Opportunities and Challenges"],"prefix":"10.1053","volume":"30","author":[{"given":"Fouad T.","family":"Chebib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4963-1132","authenticated-orcid":false,"given":"Ronald D.","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1053\/j.akdh.2023.01.004_bib1","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1053\/j.ajkd.2015.07.037","article-title":"Autosomal dominant polycystic kidney disease: core curriculum 2016","volume":"67","author":"Chebib","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"10174","key":"10.1053\/j.akdh.2023.01.004_bib2","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal dominant polycystic kidney disease","volume":"393","author":"Cornec-Le Gall","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1053\/j.akdh.2023.01.004_bib3","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1681\/ASN.2015010016","article-title":"The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease","volume":"27","author":"Cornec-Le Gall","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.akdh.2023.01.004_bib4","doi-asserted-by":"crossref","first-page":"710","DOI":"10.2215\/CJN.01581105","article-title":"Incident renal events and risk factors in autosomal dominant polycystic kidney disease: a population and family-based cohort followed for 22 years","volume":"1","author":"Dicks","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"15","key":"10.1053\/j.akdh.2023.01.004_bib5","doi-asserted-by":"crossref","first-page":"e138724","DOI":"10.1172\/jci.insight.138724","article-title":"The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD","volume":"5","author":"Lavu","year":"2020","journal-title":"JCI Insight"},{"issue":"Suppl 4","key":"10.1053\/j.akdh.2023.01.004_bib6","doi-asserted-by":"crossref","first-page":"iv15","DOI":"10.1093\/ndt\/gfu017","article-title":"Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry","volume":"29","author":"Spithoven","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1053\/j.akdh.2023.01.004_bib7","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.ekir.2020.12.016","article-title":"Characteristics of patients with end-stage kidney disease in ADPKD","volume":"6","author":"Shukoor","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.akdh.2023.01.004_bib8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41572-018-0047-y","article-title":"Polycystic kidney disease","volume":"4","author":"Bergmann","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"Suppl 1","key":"10.1053\/j.akdh.2023.01.004_bib9","doi-asserted-by":"crossref","first-page":"i2","DOI":"10.1093\/ckj\/sfy103","article-title":"Management of autosomal-dominant polycystic kidney disease-state-of-the-art","volume":"11","author":"Muller","year":"2018","journal-title":"Clin Kidney J"},{"issue":"1","key":"10.1053\/j.akdh.2023.01.004_bib10","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12913-020-4974-4","article-title":"The societal economic burden of autosomal dominant polycystic kidney disease in the United States","volume":"20","author":"Cloutier","year":"2020","journal-title":"BMC Health Serv Res"},{"key":"10.1053\/j.akdh.2023.01.004_bib11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/CEOR.S75523","article-title":"Medical resource utilization and costs associated with autosomal dominant polycystic kidney disease in the USA: a retrospective matched cohort analysis of private insurer data","volume":"7","author":"Knight","year":"2015","journal-title":"Clinicoecon Outcomes Res"},{"issue":"2","key":"10.1053\/j.akdh.2023.01.004_bib12","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1053\/j.ajkd.2013.08.017","article-title":"Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study","volume":"63","author":"Miskulin","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1053\/j.akdh.2023.01.004_bib13","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/ndt\/gfv299","article-title":"Increased psychosocial risk, depression and reduced quality of life living with autosomal dominant polycystic kidney disease","volume":"31","author":"Simms","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1053\/j.akdh.2023.01.004_bib14","doi-asserted-by":"crossref","first-page":"e0230512","DOI":"10.1371\/journal.pone.0230512","article-title":"The impact of chronic kidney disease on developed countries from a health economics perspective: a systematic scoping review","volume":"15","author":"Elshahat","year":"2020","journal-title":"PLoS One"},{"issue":"25","key":"10.1053\/j.akdh.2023.01.004_bib15","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1053\/j.akdh.2023.01.004_bib16","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.akdh.2023.01.004_bib17","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1053\/j.ajkd.2018.11.001","article-title":"Addressing the need for clinical trial end points in autosomal dominant polycystic kidney disease: a report from the polycystic kidney disease outcomes Consortium (PKDOC)","volume":"73","author":"Smith","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"10.1053\/j.akdh.2023.01.004_bib18","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.2215\/CJN.05360522","article-title":"Current challenges and perspectives on developing a clinical trial design for ADPKD","volume":"17","author":"Ostroff","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.akdh.2023.01.004_bib19","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1053\/j.ajkd.2020.12.020","article-title":"Assessing risk of rapid progression in autosomal dominant polycystic kidney disease and special considerations for disease-modifying therapy","volume":"78","author":"Chebib","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.akdh.2023.01.004_bib20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ekir.2017.04.001","article-title":"Exploring novel endpoints for clinical trials in kidney disease: challenges and opportunities","volume":"2","author":"Roy-Chaudhury","year":"2017","journal-title":"Kidney Int Rep"},{"key":"10.1053\/j.akdh.2023.01.004_bib21","unstructured":"FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. Silver Spring (MD): Food and Drug Administration (US); 2016. Co-published by National Institutes of Health (US), Bethesda (MD)."},{"issue":"1","key":"10.1053\/j.akdh.2023.01.004_bib22","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2215\/CJN.00330705","article-title":"Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes","volume":"1","author":"Grantham","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.akdh.2023.01.004_bib23","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ekir.2017.01.003","article-title":"Total kidney volume is a prognostic biomarker of renal function decline and progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease","volume":"2","author":"Perrone","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.akdh.2023.01.004_bib24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/cpt.136","article-title":"Biomarker qualification: toward a multiple stakeholder framework for biomarker development, regulatory acceptance, and utilization","volume":"98","author":"Amur","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1053\/j.akdh.2023.01.004_bib27","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.akdh.2023.01.004_bib39","doi-asserted-by":"crossref","first-page":"100538","DOI":"10.1016\/j.xkme.2022.100538","article-title":"The STAGED-PKD 2-stage adaptive study with a patient enrichment strategy and treatment effect modeling for improved study design efficiency in patients with ADPKD","volume":"4","author":"Perrone","year":"2022","journal-title":"Kidney Med"},{"issue":"9903","key":"10.1053\/j.akdh.2023.01.004_bib50","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","article-title":"Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial","volume":"382","author":"Caroli","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"10.1053\/j.akdh.2023.01.004_bib51","doi-asserted-by":"crossref","first-page":"e1002777","DOI":"10.1371\/journal.pmed.1002777","article-title":"Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): a randomized, double-blind, placebo-controlled, multicenter trial","volume":"16","author":"Perico","year":"2019","journal-title":"PLoS Med"},{"issue":"19","key":"10.1053\/j.akdh.2023.01.004_bib41","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1001\/jama.2018.15870","article-title":"Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 randomized clinical trial","volume":"320","author":"Meijer","year":"2018","journal-title":"JAMA"},{"issue":"9","key":"10.1053\/j.akdh.2023.01.004_bib52","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.akdh.2023.01.004_bib54","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.akdh.2023.01.004_bib55","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1681\/ASN.2009121302","article-title":"Sirolimus therapy to halt the progression of ADPKD","volume":"21","author":"Perico","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2023.01.004_bib57","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2215\/CJN.09900915","article-title":"Effect of sirolimus on disease progression in patients with autosomal dominant polycystic kidney disease and CKD stages 3b-4","volume":"11","author":"Ruggenenti","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.akdh.2023.01.004_bib43","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1681\/ASN.2016111232","article-title":"Bosutinib versus placebo for autosomal dominant polycystic kidney disease","volume":"28","author":"Tesar","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"24","key":"10.1053\/j.akdh.2023.01.004_bib42","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease","volume":"371","author":"Schrier","year":"2014","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1053\/j.akdh.2023.01.004_bib58","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1056\/NEJMoa1402686","article-title":"Angiotensin blockade in late autosomal dominant polycystic kidney disease","volume":"371","author":"Torres","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.akdh.2023.01.004_bib59","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.kint.2021.06.013","article-title":"Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD)","volume":"100","author":"Perrone","year":"2021","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.akdh.2023.01.004_bib60","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/j.ajkd.2021.06.026","article-title":"Metformin therapy in autosomal dominant polycystic kidney disease: a feasibility study","volume":"79","author":"Brosnahan","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1053\/j.akdh.2023.01.004_bib61","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/ckj\/sfaa232","article-title":"A randomized phase 1b cross-over study of the safety of low-dose pioglitazone for treatment of autosomal dominant polycystic kidney disease","volume":"14","author":"Blazer-Yost","year":"2021","journal-title":"Clin Kidney J"},{"issue":"8","key":"10.1053\/j.akdh.2023.01.004_bib62","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.ekir.2020.06.002","article-title":"Biological efficacy and safety of niacinamide in patients with ADPKD","volume":"5","author":"El Ters","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"5","key":"10.1053\/j.akdh.2023.01.004_bib64","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2215\/CJN.08350813","article-title":"Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease","volume":"9","author":"Cadnapaphornchai","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2023.01.004_bib30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.kint.2018.11.044","article-title":"Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease","volume":"96","author":"Gansevoort","year":"2019","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.akdh.2023.01.004_bib31","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2215\/CJN.10470620","article-title":"Use of the urine-to-plasma urea ratio to predict ADPKD progression","volume":"16","author":"Heida","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.akdh.2023.01.004_bib32","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ekir.2016.08.001","article-title":"Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the TEMPO 3:4 clinical trial","volume":"1","author":"Irazabal","year":"2016","journal-title":"Kidney Int Rep"},{"issue":"11","key":"10.1053\/j.akdh.2023.01.004_bib33","first-page":"1857","article-title":"Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial","volume":"32","author":"Irazabal","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.akdh.2023.01.004_bib34","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/ndt\/gfx188","article-title":"Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial","volume":"33","author":"Cornec-Le Gall","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1053\/j.akdh.2023.01.004_bib35","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2215\/CJN.06300615","article-title":"Effect of tolvaptan in autosomal dominant polycystic kidney disease by CKD stage: results from the TEMPO 3:4 trial","volume":"11","author":"Torres","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.akdh.2023.01.004_bib36","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/jcph.880","article-title":"Pharmacokinetics and pharmacodynamics of tolvaptan in autosomal dominant polycystic kidney disease: phase 2 trials for dose selection in the pivotal phase 3 trial","volume":"57","author":"Shoaf","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1053\/j.akdh.2023.01.004_bib37","unstructured":"T.M.V. Edmund Lee, T. Owen, S. Neben, et al., RGLS4326 Increases Urinary PC1 and PC2 Levels in Individuals with Autosomal Dominant Polycystic Kidney Disease (ADPKD)."},{"issue":"6","key":"10.1053\/j.akdh.2023.01.004_bib38","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"64","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.akdh.2023.01.004_bib40","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.kint.2018.12.023","article-title":"Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease","volume":"95","author":"Yu","year":"2019","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.akdh.2023.01.004_bib44","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.ekir.2017.07.004","article-title":"Tolerability of aquaretic-related symptoms following tolvaptan for autosomal dominant polycystic kidney disease: results from TEMPO 3:4","volume":"2","author":"Devuyst","year":"2017","journal-title":"Kidney Int Rep"},{"issue":"3","key":"10.1053\/j.akdh.2023.01.004_bib46","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000456087","article-title":"Rationale and design of a clinical trial investigating tolvaptan safety and efficacy in autosomal dominant polycystic kidney disease","volume":"45","author":"Torres","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.akdh.2023.01.004_bib47","doi-asserted-by":"crossref","unstructured":"Chapman AAGB, Block GA, et al. Trial design for phase FALCON: Evaluation of the safety, tolerability, and efficacy of bardoxolone methyl in patients with autosomal dominant polycystic kidney disease (ADPKD). presented at: National Kidney Foundation virtual 2021 Spring Clinical Meetings 2021. Am J Kid Dis. 2021;77(4):552-566.","DOI":"10.1053\/j.ajkd.2021.02.060"},{"issue":"8","key":"10.1053\/j.akdh.2023.01.004_bib48","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.34067\/KID.0002372022","article-title":"Design and basic characteristics of a national patient-powered registry in ADPKD","volume":"3","author":"Hoover","year":"2022","journal-title":"Kidney360"},{"issue":"13","key":"10.1053\/j.akdh.2023.01.004_bib49","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM199403313301301","article-title":"The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group","volume":"330","author":"Klahr","year":"1994","journal-title":"N Engl J Med"}],"container-title":["Advances in Kidney Disease and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813923000046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813923000046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T15:39:15Z","timestamp":1757432355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949813923000046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2949813923000046"],"URL":"https:\/\/doi.org\/10.1053\/j.akdh.2023.01.004","relation":{},"ISSN":["2949-8139"],"issn-type":[{"value":"2949-8139","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug Development in Autosomal Dominant Polycystic Kidney Disease: Opportunities and Challenges","name":"articletitle","label":"Article Title"},{"value":"Advances in Kidney Disease and Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.akdh.2023.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the National Kidney Foundation, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}